Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation

Bone Marrow Transplantation
Anna MlynarczewskaA Lange

Abstract

A total of 110 patients (71 adults and 39 children) who received allogeneic haematopoietic stem cell transplantation from HLA-matched sibling donors were studied for the incidence of acute graft-versus-host disease (aGvHD) in relation to IFN-gamma gene microsatellite polymorphism. A strong tendency was observed towards the lower incidence of grades II-IV aGvHD in patients having an IFN-gamma 2/2 genotype as compared to the recipients with other IFN-gamma genotypes (0.12 vs 0.33, P=0.06). This relationship was independent of the intensity of conditioning regimen and diagnosis. IFN-gamma polymorphic features, together with other clinical and biological factors (patient's age, donor-recipient gender, diagnosis, conditioning regimen, transplant material and GvHD prophylaxis), were subjected to multivariate analysis for aGvHD manifestation in order to exclude indirect association of the IFN-gamma 2/2 genotype. In multivariate analysis, myeloablative therapy (OR=11.462, P=0.013), recipient age (OR=4.896, P=0.009) and lack of IFN-gamma 2/2 genotype (OR=4.311, P=0.048) were found to significantly contribute to the development of grade II-IV aGvHD, while type of GvHD prophylaxis showed less-strong influence (OR=2.963, P=0.066). Thus, it...Continue Reading

References

Nov 27, 1995·Transplantation·D M TurnerI V Hutchinson
Mar 9, 1999·European Journal of Immunogenetics : Official Journal of the British Society for Histocompatibility and Immunogenetics·V PravicaI V Hutchinson
Oct 24, 2002·Current Opinion in Hematology·Ernst Holler
Jan 28, 2003·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Michiel C WarléGerda J Bouma
Jun 26, 2003·Trends in Pharmacological Sciences·Koen Vandenbroeck, An Goris
Mar 17, 2004·Immunology Letters·Barbara WysoczanskaAndrzej Lange

❮ Previous
Next ❯

Citations

Mar 16, 2005·Current Opinion in Immunology·Loredana RuggeriAndrea Velardi
Nov 19, 2010·Expert Review of Hematology·Beatriz Martín-AntonioAlvaro Urbano-Ispizua
May 19, 2010·Expert Review of Clinical Immunology·Susan E Conway, Reza Abdi
May 28, 2008·Best Practice & Research. Clinical Haematology·A M Dickinson, E Holler
Nov 4, 2008·International Journal of Immunogenetics·A M Dickinson
Dec 5, 2012·British Journal of Haematology·Andrew C HarrisJohn E Levine
Aug 9, 2005·Current Opinion in Immunology·Anne M Dickinson, Dominique Charron
Jan 10, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Søren L PetersenLars L Vindeløv
Dec 23, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiaojin WuYuejun Liu
Jan 24, 2007·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Charles G Mullighan, Peter G Bardy
Oct 8, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kenneth R CookeBruce R Blazar
Apr 27, 2017·British Journal of Haematology·Katarzyna Bogunia-Kubik, Piotr Łacina
Sep 20, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Neill J LiptrottAndrew Owen
Nov 3, 2007·Expert Reviews in Molecular Medicine·Anne M DickinsonHannah Cullup
Jun 22, 2021·Frontiers in Immunology·Andrzej LangeEmilia Jaskuła

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.